Cellbion
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Cellbion is listed on KOSDAQ and classified under Health Care, Pharmaceuticals. Its market value is US$124.8M. In FY2025 it reported revenue of US$1.5M and an operating loss of US$6.2M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Cellbion in five facts
Where is Cellbion listed and in which sector?
Cellbion (Korean name: 셀비온) trades under KRX code 308430 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Cellbion?
Its market capitalisation was US$124.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Cellbion's latest annual revenue and operating profit?
For fiscal year 2025, Cellbion reported revenue of US$1.5M, an operating loss of US$6.2M and a net loss of US$5.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 15.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureSep 29
- [Amended] Material event report (rights offering)
Cellbion updated the terms of convertible bonds to raise US$16.9M, about 13.7% of its market value.
Capital raise · Apr 22 · 2 versions - [Amended] Material event report (convertible bonds)
Cellbion updated the terms of convertible bonds to raise US$16.9M, about 13.7% of its market value.
Capital raise · Apr 22 · 2 versions